{"id":5344,"date":"2020-09-29T12:40:05","date_gmt":"2020-09-29T10:40:05","guid":{"rendered":"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344"},"modified":"2024-04-08T13:35:30","modified_gmt":"2024-04-08T11:35:30","slug":"success-stories","status":"publish","type":"page","link":"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344","title":{"rendered":"Success stories"},"content":{"rendered":"<div class=\"flex_column av_one_full  av-animated-generic fade-in  flex_column_div av-zero-column-padding first  avia-builder-el-0  el_before_av_section  avia-builder-el-no-sibling  \" style='margin-top:0px; margin-bottom:0px; border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h2 style=\"text-align: center; font-size: 60px; line-height: 0.9em;\">Success stories<\/h2>\n<\/div><\/section><\/div>\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div><div id='av_section_1'  class='avia-section main_color avia-section-no-padding avia-no-border-styling avia-bg-style-scroll  avia-builder-el-2  el_after_av_one_full  avia-builder-el-last   container_wrap fullsize' style=' '  ><div class='container' ><div class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-5344'><div class='entry-content-wrapper clearfix'>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">DEVELOPMENT OF MULTI-OMICS TECHNOLOGIES TO TRANSLATE NEW APPROACHES IN CANCER THERAPY FASTER INTO NEW DRUGS<\/h3>\n<p>CBmed has developed and standardised multi-omics technologies that can serve as a base for future collaborations with pharmaceutical industry to accelerate the development of first-in-class drugs and therapies.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/04\/PhO_2023_1.22_SuccessStory_EN.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/04\/PhO_2023_1.22_Success-Story_DE.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">A NEW VIEW ON CANCER PATIENTS: BRINGING DATA VISUALIZATION INTO THE CLINICS<\/h3>\n<p>The combined visualization of clinical and laboratory data in tumor boards enables new insights into refractory cancer patients.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/04\/PhO_2023_1.23-SuccessStory_EN.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/04\/PhO_2023_1.23-SuccessStory_DE.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">NEXT GENERATION DRUG SCREENING FACILITATES PRECISION MEDICINE IN GLIOBLASTOMA THERARPY<\/h3>\n<p>The drug screening platform at CBmed is a substantial part of an Austrian-wide initiative to realize personalized therapies for glioblastoma treatment.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/04\/PhO_2023_2.22_SuccessStory_EN.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/04\/PhO_2023_2.22_Success-Story_DE.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">\u201cHOW DRUGS MODULATE BUGS\u201d AND \u201cHOW BUGS MODULATE DRUGS\u201d<\/h3>\n<p>Development of a customizable in vitro model of the human gut microbiome to study the interaction between drugs, diseases, and microbes.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/04\/PhO_2023_3.23-SuccessStory_EN.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/04\/PhO_2023_3.23-SuccessStory_DE.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">MICRO- AND NANOPLASTICS BREACH THE BLOOD-BRAIN BARRIER (BBB)<\/h3>\n<p>Orally administered Micro- and Nanoplastic particles (MNP) can reach the brain already two hours after exposure. Depending on its outer shell (corona), these small particles are even able to enter the highly restricted blood-brain barrier, thus posing a potential risk to sensitive neuronal structures.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/01\/2024JAN_microONE_5_2_SuccessStory3_EN_final.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/01\/2024JAN_microONE_5_2_SuccessStory3_DE_final.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">BREAKTHROUGH IN THE DETECTION OF MICRO- AND NANOPLASTICS IN TISSUE SAMPLES<\/h3>\n<p>The introduction of Optical Photothermal Infrared Spectroscopy (OPTIR) \u2013 a novel analytical technique \u2013 enables the accurate detection of micro- and nanoplastics in biological samples. This paves the way for a better understanding of potential health impacts.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/01\/2024JAN_microONE_5_1_SuccessStory2_EN_final.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/01\/2024JAN_microONE_5_1_SuccessStory2_DE_final-1.pdf\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">DETECTION OF MICROPLASTIC PARTICLES IN HUMAN URINE<\/h3>\n<p>Using flourescence microscopy, it was possible to detect microplastic particles in human urine. The exact origin of the particles and the influence of hygiene products and clothins, as well as food, are the focus of future project steps.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/01\/2024JAN_microONE_5_4_SuccessStory1_EN_final.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2024\/01\/2024JAN_microONE_5_4_SuccessStory1_DE_final.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">CAN PLASTIC FASTING AFFECT OUR MICROPLASTIC\u00a0EXPOSURE?<\/h3>\n<p>In order to analyse the previously little researched impact of micro-plastics on humans, volunteers were recruited who, by abstaining from plastic, made a valuable contribution to clarifying this question.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2023\/01\/2023JAN22_microONE_5_4_SuccessStory1-EN_final.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2023\/01\/2023JAN22_microONE_5_4_SuccessStory1-DE_final.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">MICRO- AND NANOPLASTIC INCREASES INFLAMMATORY PROCESSES IN THE GUT<\/h3>\n<p>Micro- and nanoplastic particles have become a ubiquitous ingredient in our daily life. A recent study shows the aggraving effects of these plastic particles in gastrointestinal inflammatory diseases.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2023\/01\/2023JAN22_microONE_5_2_SuccessStory2-EN_final.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2023\/01\/2023JAN22_microONE_5_2_SuccessStory2-DE_final.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">MICRO- AND NANOPLASTICS ARE PASSED ON TO NEWLY FORMED CELLS DURING CELL DIVISION<\/h3>\n<p>The uptake of the ubiquitous micro- and nanoplastic particles is highly dependent on their size. However, once accumulated these particles are passed on to the next generation of cells underlining the persistence of plastics even in humans.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2023\/01\/2023JAN22_microONE_5_2_SuccessStory1-EN_final.pdf\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2023\/01\/2023JAN22_microONE_5_2_SuccessStory1-DE_final.pdf\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">Biomarkers for Clinical Decision Support in Intensive Care<\/h3>\n<p>In intensive care, fluid balance may serve as a biomarker for critical illness. Together with the Medical University of Graz and B. Braun Melsungen AG, an in-silico model of a patients\u2019 fluid balance within the intensive care stay was developed. The model is capable of describing the patients\u2019 behaviour on fluid management in time, but also provide a prediction throughout the stay at the intensive care unit. A patent application was filed in 2018 preparing the model for translation into industrial exploitation.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2020\/09\/CBmed_SuccessStory-2018_Biosensors.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">FUSION Technology \u2013 A Systems Biology Approach Towards Predictive Biomarkers for Relapse Risk in Stage II Colon Cancer<\/h3>\n<p>Colon cancer (CC) belongs to the most commonly diagnosed malignancies among men and women in the developed world, with an estimated 140,250 new cases being diagnosed in 2018 in the US alone, including 50,630 estimated deaths in 2018. Identification of high-risk patients with stage II CC is difficult and currently defined by several clinicopathological risk factors. Although the current risk definition for stage II CC-patients is still recommended, new prognostic and predictive markers for\u00a0 patients potentially profiting from adjuvant chemotherapy (CTX) represent a clinical need. CBmed therefore took a FUSION Technology \u2013 assisted multiplatform approach towards biomarker discovery for stage II colon cancer risk prediction.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2020\/09\/CBmed_SuccessStory-2018_FUSION.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">CLINICAL DOCUMENT PROCESSING FOR BIOMARKER RESEARCH<\/h3>\n<p>The CBmed project DBM4PM (Digital Biomarkers for Precision Medicine) builds upon the project Innovative Use of Information for Clinical Care and Biomarker Research (IICCAB), which was a crucial achievement of the first CBmed funding period which resulted in a clinical document processing solution.<br \/>\nThis so-called NLP (natural language processing) pipeline is tailored to clinical narratives from the Styrian hospital network KAGes, from which it extracts meaningful pieces of information, so-called &#8220;digital biomarkers&#8221; (mention of diseases, phenotypes, risk factors, scores, drugs in electronic health records) in a standardised form. The use of international terminology standards like SNOMED CT is a central asset.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2020\/09\/Success-story-2019_EN_FP2_1.20.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2020\/09\/Success-story-2019_DE_FP2_1.20.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: Justify;\">PROTON PUMP INHIBITOR-ASSOCIATED DAMAGE OF THE MICROBIOME<\/h3>\n<p>Gastric acid is a crucial part of the gastrointestinal tract. It is involved in digestion and the extraction of important micronutrients but it also effectively kills<br \/>\nfood-borne pathogens. In some cases, such as peptic ulcer disease or gastritis, the production of gastric acid needs to be decreased by proton pump inhibitors (PPI), in German called \u201cstomach protectors\u201d. Long-term use of this drug leaves the body without the gastric barrier, an important firewall not only against pathogens but also against bacteria from the oral cavity that can colonize the lower intestinal tract and cause inflammation and other side effects. In chronically ill patients, prolonged use of PPI is linked to the development of complications or even mortality. In this project, we identified transnational, disease-independent biomarkers for the colonization of the intestine with oral bacteria and test new strategies to remove the oral bacteria from the intestine without damaging the original gut microbiome.<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2020\/09\/Success-story-2019_EN_FP2_3.23.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2020\/09\/Success-story-2019_DE_FP2_3.23.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3 id=\"journals\" style=\"text-align: left;\">PESI MS<\/h3>\n<p>In a COMET-funded project running from 2015 to 2018, a biomarker for the diagnosis and monitoring of pulmonary hypertension (PH) was identified and<br \/>\npatented under the leadership of the K1 Center CBmed, together with the scientific partners Ludwig Boltzmann Institute for Lung Vascular Research, Medical University Graz and Joanneum Research Forschungsgesellschaft. Pulmonary hypertension (PH) is characterized by elevated blood pressure in the pulmonary circulation and causes a significantly reduced survival rate of 53.6% after 5 years. The prevalence is 5-25 cases per million people, although the actual rate of the disease is probably underestimated. An essential factor influencing survival is the early and adequate diagnosis of the disease. In particular, the broad and unspecific clinical symptoms, for example shortness of breath, syncope, tiredness and chest pain, represents a major challenge in clinical practice. An incomplete, delayed or inadequate diagnosis is therefore common and occurs in up to 85% of all patients at risk. The current gold standard, the measurement of pulmonary arterial pressure using a cardiac catheter, is extremely invasive, costly and carries an elevated risk of mortality. Up to date there are no alternative, specific and less invasive methods for diagnosis and monitoring of PH available<\/p>\n<p><a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2020\/09\/Success-story-2019_EN_FP2_PESI-MS.pdf\" target=\"_blank\" rel=\"noopener\">Read the full story here<\/a><br \/>\n<a href=\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2020\/09\/Success-story-2019_DE_FP2_PESI-MS.pdf\" target=\"_blank\" rel=\"noopener\">Lesen Sie hier die ganze Geschichte<\/a><\/p>\n<\/div><\/section>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":12,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5344","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.13 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Success stories | CBmed GmbH Center for Biomarker Research in Medicine<\/title>\n<meta name=\"description\" content=\"Success stories from the past years of CBmed.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Success stories | CBmed GmbH Center for Biomarker Research in Medicine\" \/>\n<meta property=\"og:description\" content=\"Success stories from the past years of CBmed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344\" \/>\n<meta property=\"og:site_name\" content=\"CBmed GmbH Center for Biomarker Research in Medicine\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-08T11:35:30+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344\",\"url\":\"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344\",\"name\":\"Success stories | CBmed GmbH Center for Biomarker Research in Medicine\",\"isPartOf\":{\"@id\":\"https:\/\/services.cbmed.at\/html\/old\/#website\"},\"datePublished\":\"2020-09-29T10:40:05+00:00\",\"dateModified\":\"2024-04-08T11:35:30+00:00\",\"description\":\"Success stories from the past years of CBmed.\",\"breadcrumb\":{\"@id\":\"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/services.cbmed.at\/html\/old\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Success stories\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/services.cbmed.at\/html\/old\/#website\",\"url\":\"https:\/\/services.cbmed.at\/html\/old\/\",\"name\":\"CBmed GmbH Center for Biomarker Research in Medicine\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/services.cbmed.at\/html\/old\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/services.cbmed.at\/html\/old\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/services.cbmed.at\/html\/old\/#organization\",\"name\":\"CBmed GmbH Center for Biomarker Research in Medicine\",\"url\":\"https:\/\/services.cbmed.at\/html\/old\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/services.cbmed.at\/html\/old\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2019\/10\/cbmedlogo.png\",\"contentUrl\":\"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2019\/10\/cbmedlogo.png\",\"width\":728,\"height\":216,\"caption\":\"CBmed GmbH Center for Biomarker Research in Medicine\"},\"image\":{\"@id\":\"https:\/\/services.cbmed.at\/html\/old\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Success stories | CBmed GmbH Center for Biomarker Research in Medicine","description":"Success stories from the past years of CBmed.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Success stories | CBmed GmbH Center for Biomarker Research in Medicine","og_description":"Success stories from the past years of CBmed.","og_url":"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344","og_site_name":"CBmed GmbH Center for Biomarker Research in Medicine","article_modified_time":"2024-04-08T11:35:30+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344","url":"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344","name":"Success stories | CBmed GmbH Center for Biomarker Research in Medicine","isPartOf":{"@id":"https:\/\/services.cbmed.at\/html\/old\/#website"},"datePublished":"2020-09-29T10:40:05+00:00","dateModified":"2024-04-08T11:35:30+00:00","description":"Success stories from the past years of CBmed.","breadcrumb":{"@id":"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/services.cbmed.at\/html\/old\/?page_id=5344"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/services.cbmed.at\/html\/old\/?page_id=5344#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/services.cbmed.at\/html\/old\/"},{"@type":"ListItem","position":2,"name":"Success stories"}]},{"@type":"WebSite","@id":"https:\/\/services.cbmed.at\/html\/old\/#website","url":"https:\/\/services.cbmed.at\/html\/old\/","name":"CBmed GmbH Center for Biomarker Research in Medicine","description":"","publisher":{"@id":"https:\/\/services.cbmed.at\/html\/old\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/services.cbmed.at\/html\/old\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/services.cbmed.at\/html\/old\/#organization","name":"CBmed GmbH Center for Biomarker Research in Medicine","url":"https:\/\/services.cbmed.at\/html\/old\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/services.cbmed.at\/html\/old\/#\/schema\/logo\/image\/","url":"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2019\/10\/cbmedlogo.png","contentUrl":"https:\/\/services.cbmed.at\/html\/old\/wp-content\/uploads\/2019\/10\/cbmedlogo.png","width":728,"height":216,"caption":"CBmed GmbH Center for Biomarker Research in Medicine"},"image":{"@id":"https:\/\/services.cbmed.at\/html\/old\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/services.cbmed.at\/html\/old\/index.php?rest_route=\/wp\/v2\/pages\/5344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/services.cbmed.at\/html\/old\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/services.cbmed.at\/html\/old\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/services.cbmed.at\/html\/old\/index.php?rest_route=\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/services.cbmed.at\/html\/old\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5344"}],"version-history":[{"count":17,"href":"https:\/\/services.cbmed.at\/html\/old\/index.php?rest_route=\/wp\/v2\/pages\/5344\/revisions"}],"predecessor-version":[{"id":9167,"href":"https:\/\/services.cbmed.at\/html\/old\/index.php?rest_route=\/wp\/v2\/pages\/5344\/revisions\/9167"}],"wp:attachment":[{"href":"https:\/\/services.cbmed.at\/html\/old\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}